Oura is going public, leaning into the health data narrative that has sustained its premium valuation. Simultaneously, The Verge's review of the Fairphone 6 Plus is a love letter to a phone that costs less and is designed to be boring forever. These two stories are not in the same conversation in the tech press. They should be.
The Oura IPO and the Health Data Premium
Oura's path to public markets runs through health data. The ring tracks sleep, heart rate variability, temperature, and activity. The pitch is that continuous passive monitoring produces longitudinal health data more valuable than any single doctor's appointment. TurboFund's healthtech investor list tracks the VC thesis here: wearables that generate proprietary data become platforms, and platforms get multiples that hardware alone cannot justify. The risk is that rivals are compressing the hardware advantage fast, and the data moat depends on users trusting the company with information that is intimate in ways fitness data typically is not.
Fairphone's Repairability Bet Against Planned Obsolescence
The Fairphone 6 Plus is, by the reviewer's own admission, an extremely average midrange Android phone. The reviewer could not be more thrilled. The point is that a phone that is repairable, uses ethically sourced materials, and does not require replacement every two years is a political object as much as a consumer one. Nicolas Cevallos's essay on modern heirlooms frames this precisely: buying for forever is a different cognitive register than buying for now. The Fairphone asks you to care about the object rather than the upgrade. Oura asks you to trust your body data to a company about to answer to shareholders. Both are bets on what hardware means after the smartphone as status object has peaked. They are just betting on opposite answers.